NRAS and metastatic melanoma: CTC populations decreased in patients after receiving immunotherapy for BRAF, NRAS, and KIT mutant alleles in metastatic melanoma, highlighting the utility of monitoring CTC response to treatment to identify BRAF-mutant non-responders (Hong et al., 2018).